TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02339896

Intervention type: BIOLOGICAL
Intervention: rabies vaccine
Description: rabies vaccine 0.1 ml intradermal two site for 4 times

Intervention type: BIOLOGICAL
Intervention: rabies vaccine
Description: rabies vaccine 0.1 ml intradermal two site for 4 times
Study: NCT03749447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl capsules
Study: NCT03810534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect-Home
Description: Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
Study: NCT03091647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure intervention
Description: Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
Study: NCT00015821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03183102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: 2 months of dietary flaxseed supplementation
Study: NCT02448667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FAXE Kondi
Description: Sucrose and glucose containing softdrink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Faxe Kondi Free
Description: Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
Study: NCT02627508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: orally administered Pregnenolone capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered placebo capsules
Study: NCT00644462

Intervention type: DEVICE
Intervention: PulmoTrack® 2010 with WIM-PC™ Technologies
Description: wheeze detection during dynamic bronchial situations in infants

Intervention type: DEVICE
Intervention: PulmoTrack® 2010 with WIM-PC™ Technologies
Description: wheeze detection during dynamic bronchial situations in infants
Study: NCT02597907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant 80 mg is given to all patients before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant 80 mg is given to all patients before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
Study: NCT03701295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinometostat
Description: Given IV
Study: NCT01303120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined nerve blocks
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: Patient controlled analgesia with morphine
Study: NCT02842944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: open loop weaning group (Beacon)
Description: mechanical ventilation following advice from the Beacon Caresystem

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Standardized routine care
Study: NCT03940508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Connections Intervention
Description: The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPT-A
Description: IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-A
Description: IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
Study: NCT00771303

Intervention type: OTHER
Intervention: Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.
Study: NCT03279055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
Study: NCT01295567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: prior to CABG surgery 3 day treatment with placebo capsules twice daily
Study: NCT00596596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 0,5 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg prucalopride
Description: 2 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg prucalopride
Description: 4 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study: NCT03509116

Intervention type: OTHER
Intervention: Observations, documents
Description: Consultation observations, documentary analysis

Intervention type: OTHER
Intervention: Observations, documents
Description: Consultation observations, documentary analysis

Intervention type: OTHER
Intervention: Interviews, key stakeholders, documents
Description: Qualitative interviews, key stakeholders, documentary analysis

Intervention type: OTHER
Intervention: Interviews, key stakeholders, documents
Description: Qualitative interviews, key stakeholders, documentary analysis

Intervention type: OTHER
Intervention: Interviews, key stakeholders, documents
Description: Qualitative interviews, key stakeholders, documentary analysis
Study: NCT04384822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Group
Description: Mind-body exercise intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I Group
Description: First-line clinically recommended non-pharmacological treatment of insomnia
Study: NCT02221102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: non-steroidal anti-inflammatory drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban
Description: orally active direct factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban
Description: orally active direct factor Xa inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00219440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actos plus standard diet
Description: Actos plus standard diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actos plus structured diet
Description: Actos plus structured diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metformin plus standard diet
Description: Metformin plus standard diet
Study: NCT02294188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient (SHIELD)
Description: Spatial Repellent Product

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ingredient
Description: Transfluthrin (Active ingredient)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study: NCT02648984

Intervention type: OTHER
Group type: OTHER
Intervention: The intervention is performing an exercise test
Description: Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test

Intervention type: OTHER
Group type: OTHER
Intervention: The intervention is performing an exercise test
Description: Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
Study: NCT03098940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol
Study: NCT01800201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle, Incentives, Social Influence
Description: The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
Study: NCT04144803

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral near-infrared spectroscopy
Description: Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral near-infrared spectroscopy
Description: Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
Study: NCT00118261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00030420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
Study: NCT04414280

Intervention type: DEVICE
Intervention: Medtronic MiniMed 670G
Description: The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.

Intervention type: DEVICE
Intervention: Medtronic MiniMed 780G
Description: The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.

Intervention type: DEVICE
Intervention: Tandem Control-IQ
Description: The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
Study: NCT01872910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023703
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study: NCT01282801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study: NCT04072341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis Period (Green Propolis 250mg/day)
Description: Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Period
Description: In the control period they will only follow standard treatment for their comorbidities.
Study: NCT00100932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 28 Day Cycle
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 21 Day Cycle
Description: E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
Study: NCT01602757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera
Description: Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3.
Study: NCT01576367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACZ885
Study: NCT03354650

Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to determine causative organisms of neonatal sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to determine causative organisms of neonatal sepsis
Study: NCT05298098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline Solution
Description: Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
Study: NCT00595270

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IC51
Study: NCT00633919

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone(TM) Dermatophagoides mix
Description: Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual immunotherapy once daily for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol inhaler
Description: 200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol inhaler
Description: 200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol inhaler
Description: 80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide/formoterol inhaler
Description: 80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: 5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone tablet
Description: 5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine tablet
Description: 5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desloratadine tablet
Description: 5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)